A Randomized, Double-Masked Trial of Prophylactic Indomethacin Tocolysis Versus Placebo in Women with Premature Rupture of Membranes

ABSTRACT

Preterm premature rupture of membranes (PPROM) complicates 3% of pregnancies and frequently results in preterm birth, often within 48 hours of membrane rupture. Our objective was to determine if subjects with PPROM between 24 and 31⁶/₇ weeks' gestation benefit from a 48-hour course of prophylactic indomethacin tocolysis. This was a double-masked randomized controlled trial. Subjects with PPROM between 24 and 31⁶/₇ weeks' gestation were randomized to receive indomethacin or placebo for 48 hours in addition to corticosteroids and latency antibiotics. The primary outcome of the study was delivery within 48 hours. Maternal and neonatal outcomes were also compared. This study was concluded prematurely due to slow accrual after a total of 50 subjects were enrolled. A total of 23/25 (92%) subjects in the indomethacin group remained pregnant beyond 48 hours compared with 20/22 (90.9%) in the placebo group (relative risk, 1.01; 95% confidence interval, 0.84 to 1.21). The latency period medians and interquartile ranges were similar between the two groups [indomethacin 193 (92 to 376.5) hours versus placebo 199 (77.5 to 459) hours, p = 0.91], and no differences were noted in any maternal or neonatal secondary outcomes. This limited study demonstrates no benefit with the use of prophylactic indomethacin tocolysis for women with PPROM.

Preterm premature rupture of membranes - tocolysis - indomethacin - preterm delivery

REFERENCES

• 1 Mercer B M. Preterm premature rupture of the membranes.  Obstet Gynecol. 2003;  101 178-193
• 2 Effect of corticosteroids for fetal maturation on perinatal outcomes.  NIH Consens Statement. 1994;  12 1-24
• 3 Levy D L, Warsof S L. Oral ritodrine and preterm premature rupture of membranes.  Obstet Gynecol. 1985;  66 621-623
• 4 Christensen K K, Ingemarsson I, Leideman T, Solum T, Svenningsen N. Effect of ritodrine on labor after premature rupture of the membranes.  Obstet Gynecol. 1980;  55 187-190
• 5 Garite T J, Keegan K A, Freeman R K, Nageotte M P. A randomized trial of ritodrine tocolysis versus expectant management in patients with premature rupture of membranes at 25 to 30 weeks of gestation.  Am J Obstet Gynecol. 1987;  157 388-393
• 6 How H Y, Cook C R, Cook V D, Miles D E, Spinnato J A. Preterm premature rupture of membranes: aggressive tocolysis versus expectant management.  J Matern Fetal Med. 1998;  7 8-12
• 7 Myatt L, Lye S J. Expression, localization and function of prostaglandin receptors in myometrium.  Prostaglandins Leukot Essent Fatty Acids. 2004;  70 137-148
• 8 Nelson L H, Meis P J, Hatjis C G, Ernest J M, Dillard R, Schey H M. Premature rupture of membranes: a prospective, randomized evaluation of steroids, latent phase, and expectant management.  Obstet Gynecol. 1985;  66 55-58
• 9 Schulz K F, Grimes D A. Sample size calculations in randomised trials: mandatory and mystical.  Lancet. 2005;  365 1348-1353
• 10 Antes G, Chalmers I. Under-reporting of clinical trials is unethical.  Lancet. 2003;  361 978-979
• 11 Schulz K F, Grimes D A. Multiplicity in randomised trials II: subgroup and interim analyses.  Lancet. 2005;  365 1657-1661
• 12 Wolfensberger A, Zimmermann R, von Mandach U. Neonatal mortality and morbidity after aggressive long-term tocolysis for preterm premature rupture of the membranes.  Fetal Diagn Ther. 2006;  21 366-373
• 13 Loe S M, Sanchez-Ramos L, Kaunitz A M. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.  Obstet Gynecol. 2005;  106 173-179